ZLDPF News and Press, Zealand Pharma A/S Ord From 06/06/24

Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark, June 6, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) today announced that an embargoed ...

2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...

Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency Copenhagen, Denmark, May 31, 2024 – Zealand Pharma A/S (Nasdaq: Z...

Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and developm...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-24 10:40:44 ET More on Zealand Pharma Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment Zealand Pharma A/S (ZEAL) Q4 2023 Earnings Call Transcript Historical earnings data fo...

Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean weight loss of up to 4.3% after 12 weeks with low doses of dapiglutide treatmen...

2024-05-21 10:29:09 ET More on Weight Loss Drugs Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead Genetics may determine who responds well to Wegovy: report One in eight U.S. adults admits to GLP-1 usage as public aware...

2024-05-20 08:20:00 ET Summary The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals. Amgen sort-of-announced positive results on its candidate, MariTide. Boeh...

2024-05-16 11:37:03 ET Zealand Pharma A/S (ZLDPF) Q1 2024 Results Conference Call May 16, 2024 08:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO David Kendall - CMO Henriette Wennicke - CFO Conference Call Partic...